The Molecular Basis of Ocular Aging: Mechanisms, Pathologies, and Emerging Therapeutics.
Key claim: Four interacting hallmarks of aging—mitochondrial dysfunction, loss of proteostasis, cellular senescence, and epigenetic drift—drive age-related eye diseases through tissue-specific routes, and targeting nodes such as senolytics, mitochondria, NAD+ metabolism, and partial epigenetic reprogramming may restore ocular tissue resilience beyond symptom management.
Abstract
Age-related eye diseases (AREDs)-including age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy-are leading causes of permanent blindness. Current treatments manage clinical manifestations but do not halt the molecular processes that drive disease progression. This limitation has shifted attention toward “geroscience,” a strategy that targets the fundamental biology of aging rather than treating each disease in isolation. Four key hallmarks of aging-mitochondrial dysfunction, loss of proteostasis, cellular senescence, and epigenetic drift-are widely implicated in AREDs. We review evidence that these hallmarks do not act independently; instead, they form an interactive, self-reinforcing network. The way this network engages differs from tissue to tissue. In the high-energy environment of the retinal pigment epithelium, mitochondrial dysfunction dominates and drives AMD. In the mechanically stressed trabecular meshwork ™, senescence and epigenetic drift take precedence, leading to glaucoma. In the neurovascular unit, chronic hyperglycemia routes the same network into a metabolic-epigenetic amplification loop that sustains diabetic retinopathy. The same aging mechanisms, routed through distinct tissue contexts, thus produce divergent clinical phenotypes. We also evaluate emerging therapies, including senolytics, mitochondria-targeted agents, and partial epigenetic reprogramming, and identify key intervention nodes such as NLRP3, p62, and NAD⁺ metabolism. Dismantling these pathological feedback loops offers a path beyond symptom management toward combination strategies that restore tissue resilience.
Why this matters
The eye is emerging as a favored proving ground for geroscience because delivery is local, disease burden (AMD, glaucoma, diabetic retinopathy) is age-driven, and readouts are quantifiable. This review formalizes a tissue-context model — RPE vs trabecular meshwork vs neurovascular unit — that lets the vault track how the four hallmarks map to distinct ocular indications and where senolytic, mitochondrial, NAD+, and partial-reprogramming pitches actually have preclinical scaffolding versus purely mechanistic hope.